Hereditary Angioedema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hereditary Angioedema Clinical Trials Market Report Overview
The hereditary angioedema (HAE) clinical trial market research report provides an overview of the hereditary angioedema clinical trials scenario. The report provides top-line data relating to the clinical trials on hereditary angioedema. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America |
Key Countries | The US, Germany, the UK, Canada, Italy, Hungary, Israel, Spain, Australia, and France |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Takeda Pharmaceutical Co Ltd, BioCryst Pharmaceuticals Inc, Pharming Group NV, CSL Ltd, Pharvaris NV, Kalvista Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Quad UK Bidco Ltd, and Watch Bidco Ltd |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Hereditary Angioedema Clinical Trials Market Segmentation by Regions and Countries
The key regions in the hereditary angioedema clinical trials market are Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America. In 2023, Europe dominates the market with the highest number of clinical trials conducted on hereditary angioedema followed by North America.
In a country-wise analysis, as of January 2023, the US has the highest number of hereditary angioedema clinical trials, followed by Germany, the UK, Canada, Italy, Hungary, Israel, Spain, Australia, and France.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the UK has the highest proportion of hereditary angioedema to immunology clinical trials as of January 2023. The United Kingdom has the highest proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology clinical trials as of January 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of hereditary angioedema to immunology clinical trials as of January 2023. Turkey has the highest proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology clinical trials as of January 2023.
Hereditary Angioedema Clinical Trials Analysis by Regions, 2023 (%)
Buy the full report for more regional insights into the hereditary angioedema clinical trials market, download a free report sample
Hereditary Angioedema Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the hereditary angioedema clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominated the market in 2023.
Hereditary Angioedema Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the hereditary angioedema clinical trials market, buy the full report or download a free report sample
Hereditary Angioedema Clinical Trials Market - Competitive Landscape
Some of the leading sponsors in the hereditary angioedema clinical trials market are Takeda Pharmaceutical Co Ltd, BioCryst Pharmaceuticals Inc, Pharming Group NV, CSL Ltd, Pharvaris NV, Kalvista Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Quad UK Bidco Ltd, and Watch Bidco Ltd. Takeda Pharmaceutical Co Ltd has conducted the highest number of hereditary angioedema clinical trials and is followed by BioCryst Pharmaceuticals Inc and Pharming Group NV.
Hereditary Angioedema Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy the full report to know more about the leading players in the hereditary angioedema clinical trials market, download a free report sample
Segments Covered in the Report
Hereditary Angioedema Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Hereditary Angioedema Clinical Trials Country Outlook (2023)
- The US
- Germany
- The UK
- Canada
- Italy
- Hungary
- Israel
- Spain
- Australia
- France
Hereditary Angioedema Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
BioCryst Pharmaceuticals Inc
Pharming Group NV
CSL Ltd
Pharvaris NV
Kalvista Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Quad UK Bidco Ltd
Watch Bidco Ltd
Advanced Medical Services GmbH
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the hereditary angioedema clinical trials market?
The key regions in the hereditary angioedema clinical trials market are Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America.
-
Which are the key countries in the hereditary angioedema clinical trials market?
The key countries in the hereditary angioedema clinical trials market are the US, Germany, the UK, Canada, Italy, Hungary, Israel, Spain, Australia, and France.
-
What are the key sponsor types in the hereditary angioedema clinical trials market?
The key sponsor types in the hereditary angioedema clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the hereditary angioedema clinical trials market?
Some of the leading sponsors in the hereditary angioedema clinical trials market are Takeda Pharmaceutical Co Ltd, BioCryst Pharmaceuticals Inc, Pharming Group NV, CSL Ltd, Pharvaris NV, Kalvista Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Quad UK Bidco Ltd, and Watch Bidco Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.